We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA approved Fasenra for the treatment of hypereosinophilic syndrome. How benralizumab is better than analogues, and why this is a strategy shift for AstraZeneca. Learn the prospects.